Cancer Stem Cells' Biomarker ALDH1&2 Increased Expression in Erosive Oral Lichen Planus Compared to Oral Leukoplakia.
aldh
oral leukoplakia
oral lichen planus
oral lichenoid reaction
skin inflammation
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
28
08
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
ALDH1&2 has been considered an oral cancer stem cell (CSC) marker. Oral carcinogenesis is a process that usually passes through oral potentially malignant disorders (OPMD). Oral lichen planus (OLP) consists of immune-related chronic disorders that have been included in the OPMDs due to their possible transformation into oral cancer. The aim of this study was to investigate the early presence of ALDH1&2 in OLP compared to early oral leukoplakias (OL), especially mildly and non-dysplastic OL. The study type is experimental, and the study design is characterized as semiquantitative research which belongs to the branch of experimental research. The study sample consisted of paraffin-embedded OLP biopsy samples from the archives of the Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Greece, during the period 2009-2019. The study sample contained 24 cases of OLP (14 erosive and 10 reticular) and 30 cases of OL (16 cases of moderately and severely dysplastic OL and 14 cases of mildly and non-dysplastic OL). The CSC-related biomarker ALDH1&2 was examined using semiquantitative immunohistochemistry (monoclonal antibody sc-166362, Santa Cruz Biotechnology, Dallas, Texas, USA, 1:100). ALDH1&2 expression was evaluated through a scale of 1 to 3 depending on the percentage of positive epithelial cells and was compared to normal epithelium as well as cases of OL (the most prominent OPMD). The statistical analysis was performed with the Pearson chi-square test and the significance level was set at p≤0.05. The cytoplasmic staining of ALDH1&2 was observed mostly in the epithelial cells of the basal layer of the epithelium of OLP. Overall, this expression was significantly increased compared to normal epithelium. In addition, statistically significantly higher expression of ALDH1&2 was observed in the erosive form of OLP. Interestingly, this OLP positivity was higher compared to mild and non-dysplastic leukoplakias (p<0.001). ALDH1&2 is a confirmed CSC marker that was found to be clearly increased in OLP and characteristically in erosive OLP epithelium for the first time. Noteworthy, it was more prominent in erosive OLP rather than in mildly and non-dysplastic OL. Whether this pattern of expression raises the red flag of an early epithelial "CSC" phenotype in OLP or that ALDH1&2 expression indicates a response to the OLP inflammatory process requires further investigation.
Identifiants
pubmed: 37772212
doi: 10.7759/cureus.44278
pmc: PMC10532032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e44278Informations de copyright
Copyright © 2023, Zisis et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pathol Int. 2012 Oct;62(10):684-9
pubmed: 23005595
Med Oral Patol Oral Cir Bucal. 2014 Jul 01;19(4):e386-90
pubmed: 24905952
Proc Finn Dent Soc. 1988;84 Suppl 3:1-93
pubmed: 3260669
Mol Med Rep. 2012 Apr;5(4):1116-20
pubmed: 22307065
Cureus. 2023 May 9;15(5):e38807
pubmed: 37303447
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Dec;151(2):333-9
pubmed: 18345274
J Oral Pathol Med. 2015 Jan;44(1):1-14
pubmed: 24329772
An Bras Dermatol. 2017 Mar-Apr;92(2):168-171
pubmed: 28538873
Biochem Biophys Res Commun. 2009 Jul 31;385(3):307-13
pubmed: 19450560
Bioessays. 2009 Oct;31(10):1038-49
pubmed: 19708024
Scand J Dent Res. 1987 Apr;95(2):174-80
pubmed: 3551045
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):144-153
pubmed: 30315141
Cell Death Dis. 2023 Jan 20;14(1):45
pubmed: 36670098
J Oral Pathol Med. 2013 Feb;42(2):148-53
pubmed: 22725270
Clin Dermatol. 2000 Sep-Oct;18(5):533-9
pubmed: 11134848
Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):537-542
pubmed: 29189260
Cureus. 2023 Jun 22;15(6):e40836
pubmed: 37489188
Int J Cancer. 2013 Feb 15;132(4):868-74
pubmed: 22782852
Quintessence Int. 2020;51(2):156-161
pubmed: 31942576
Front Oncol. 2017 Jun 02;7:112
pubmed: 28626726
Oral Oncol. 2009 Apr-May;45(4-5):317-23
pubmed: 18674954
Cell Cycle. 2011 May 1;10(9):1378-84
pubmed: 21552008
Biophys Rep. 2018;4(4):178-188
pubmed: 30310855
Mol Clin Oncol. 2020 Nov;13(5):42
pubmed: 32874572